Hydroxyurea – 25 g

Brand:
Cayman
CAS:
127-07-1
Storage:
-20
UN-No:
Non-Hazardous - /

Hydroxyurea is an antineoplastic agent that inhibits DNA replication and cell proliferation and induces cell cycle arrest in the G1/S phase.{38524} It inhibits proliferation of NCI H460 human lung cancer cells in vitro (IC50 = 0.56 mM).{38533} Hydroxyurea reduces ribonucleoside diphosphate reductase (RNR) activity by 75% when used at a concentration of 5 mM via degradation of its active site tyrosyl radical.{38524,38534} In a humanized mouse model of sickle cell disease (SCD), it reduces leukocyte adhesion and extravasation via NO production and a cGMP-dependent pathway.{38535} Hydroxyurea also inhibits HIV-1 viral replication in peripheral blood mononuclear cells (PBMCs) in a dose-dependent manner with an IC90 value of 0.4 mM.{38536,38528} Formulations containing hydroxyurea have been used to treat cancer, SCD, and psoriasis.{38524,38525,38527}  

 

Available on backorder

SKU: 23725 - 25 g Category:

Description

An antineoplastic agent; inhibits DNA replication and cell proliferation and induces cell cycle arrest in the G1/S phase; inhibits proliferation of NCI H460 human lung cancer cells in vitro (IC50 = 0.56 mM); reduces RNR activity by 75% when used at a concentration of 5 mM via degradation of its active site tyrosyl radical; reduces leukocyte adhesion and extravasation in a humanized mouse model of SCD via NO production and a cGMP-dependent pathway; inhibits HIV-1 viral replication in PBMCs (IC90 = 0.4 mM),


Formal name: N-hydroxy-urea

Synonyms:  NCI C04831|NSC 32065

Molecular weight: 76.1

CAS: 127-07-1

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals||Research Area|Cancer|Cell Cycle|G1||Research Area|Immunology & Inflammation|Autoimmunity||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS